1 unchanged sentence
Exhibit Title
−Removed: Agreement and Plan of Merger, dated as of October 5, 2020, by and among BridgeBio Pharma, Inc., Eidos Therapeutic, Inc., Globe Merger Sub I, Inc.
+Added: Agreement and Plan of Merger, dated as of October 5, 2020, by and among BridgeBio Pharma, Inc., Eidos Therapeutics, Inc., Globe Merger Sub I, Inc.
and Globe Merger Sub II, Inc.
6 unchanged sentences
June 24, 2019
−Removed: Registration Rights Agreement, dated June 26, 2019, among the Registrant and certain of its stockholders .
+Added: Form of Registration Rights Agreement, dated June 26, 2019, among the Registrant and certain of its stockholders .
June 24, 2019
2 unchanged sentences
March 10, 2020
−Removed: Form of Global Note, representing BridgeBio Pharma, Inc.’s 2.50% Convertible Senior Notes due 2027 .
+Added: Form of Global Note, representing BridgeBio Pharma, Inc.’s 2.50% Convertible Senior Notes due 2027 (included as Exhibit A to the Indenture filed as Exhibit 4.1) .
March 10, 2020
2 unchanged sentences
January 29, 2021
−Removed: Form of Global Note, representing BridgeBio Pharma, Inc.’s 2.25% Convertible Senior Notes due 2029
+Added: Form of Global Note, representing BridgeBio Pharma, Inc.’s 2.25% Convertible Senior Notes due 2029 ( included as Exhibit A to the Indenture filed as Exhibit 4.1)
January 29, 2021
+Added: Consulting Agreement between Frank McCormick and the Registrant, effective as of January 1, 2021.
+Added: February 23, 2023
+Added: Amendment No.
+Added: 1 to Consulting Agreement between Frank McCormick and the Registrant, effective as of March 3, 2022.
+Added: February 23, 2023
+Added: Amendment No.
+Added: 2 to Consulting Agreement between Frank McCormick and the Registrant, effective as of March 3, 2023.
+Added: February 23, 2023
+Added: BridgeBio Pharma, Inc.
+Added: Amended and Restated 2019 Inducement Equity Plan, effective February 10, 2023.
+Added: Filed herewith
Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 .
22 unchanged sentences
Filed herewith
+Added: # Indicates a management contract or any compensatory plan, contract or arrangement.
Certain confidential portions (indicated by brackets and asterisks) have been omitted from this exhibit in accordance with the rules of the Securities and Exchange Commission because such information (i) is not material and (ii) is the type that the Registrant treats as private or confidential.
4 unchanged sentences
BridgeBio Pharma, Inc.
−Removed: November 3, 2022
/s/ Neil Kumar
2 unchanged sentences
(Principal Executive Officer)
−Removed: November 3, 2022
/s/ Brian Stephenson
3 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.